Deals

4DTM Goes It Alone After Roche Pulls Out of Gene Therapy Trials

By Karen Blum | July 20, 2021

In 2018, 4D Molecular Therapeutics announced it was expanding its 2015 research agreement with Roche to develop and commercialize multiple ophthalmology products. This summer, things…

Read More

Samsung Bioepis Brings Heat to Race for Anti-VEGF Biosimilars

By Rich Kirkner | July 6, 2021

South Korea-based Samsung Bioepis Co. has gained another leg up in the race for an anti-VEGF biosimilar to treat retinal diseases in the lucrative US…

Read More
OIS Index Q2

OIS Index Rallies Back from COVID-Driven Decline

By Michael Lachman | July 9, 2020

The OIS Index of ophthalmic stocks staged a strong comeback in Q2, gaining 21.4%, in line with the overall US stock market as measured by…

Read More
With Amblyotech Buy, Novartis Makes a Transformation to the Ophthalmic Device Arena

With Amblyotech Buy, Novartis Makes a Transformation to the Ophthalmic Device Arena

By Christine Bahls | June 10, 2020

Most transformations are predictable: A caterpillar will turn into a butterfly; a cell will be genetically altered should extraneous DNA enter its membrane. Predictable would…

Read More
AbbVie’s Big Bet to Diversify with Allergan Pays Off So Far

AbbVie’s Big Bet to Diversify with Allergan Pays Off So Far

By Steve Lenier | May 20, 2020

Now that it has closed on its $63 billion acquisition of Allergan, AbbVie has significantly expanded its revenue base, which could help cushion the blow…

Read More
Covid-19 Impact on Healthcare Company Valuations & Financings

Covid-19 Impact on Healthcare Company Valuations & Financings

By Rich Kirkner | April 22, 2020

The turmoil in the stock market over the past month or so has sent leading healthcare indices reeling, casting a cloud over the financing that…

Read More
OIS Index: No Immunity to Coronavirus Selloff

OIS Index: No Immunity to Coronavirus Selloff

By Michael Lachman | April 8, 2020

The OIS Index of ophthalmic stocks followed global stock markets into bear market territory in Q1, declining 21.2%, in line with the overall US stock…

Read More
Verana eyes adding third registry

Verana eyes adding third registry

By Rich Kirkner | April 2, 2020

The explosion of healthcare information technology has engendered a chaotic landscape of infinite terabytes of disparate but mutually relevant data segregated in infinite silos where…

Read More
OIS@SECO In The Books

OIS@SECO In The Books

By Michelle Dalton | March 11, 2020

Last week we heard firsthand at OIS@SECO’s second annual event just what it means to be innovative in the field of optometry. Leading off the…

Read More
9 Steps to Launching a Product

9 Steps to Launching a Product

By Heather Johnson | March 3, 2020

Editor’s Note: The FDA just approved Allergan’s Durysta (bimatoprost implant) 10 mcg for lowering intraocular pressure in patients with open-angle glaucoma or ocular hypertension on…

Read More
2020’s Potential Retina Milestones

2020’s Potential Retina Milestones

By Rich Kirkner | February 26, 2020

As reports of intraocular inflammation and vasculitis have cast caution onto the uptake of the newest approved anti-VEGF drug, Novartis’ Beovu (brolucizumab), the quest to…

Read More
‘Start Up Nation’ a True Moniker

‘Start Up Nation’ a True Moniker

By Michelle Dalton | February 19, 2020

Israel’s second name is “start-up nation,” and there are anywhere from 50-70 companies developing products for the eye care industry in Israel. From a monetary…

Read More

SUBSCRIBE TO OIS NEWS

Get Our Weekly Newsletter About The Latest In Ophthalmic Innovation.

We respect your privacy and promise to never send you spam.

Something went wrong. Please check your entries and try again.